- Conditions
- Dry Eye Syndromes
- Interventions
- Carboxymethylcellulose (CMC) Artificial Tears, Preservative-free, CMC-free Artificial Tears (control)
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dry Eye Disease
- Interventions
- glycerin 0.7%/PEG 400 0.3%, polyethylene glycol 400 0.4%/propylene glycol 0.3%
- Drug
- Lead sponsor
- Calm Water Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Dry Eye Disease (DED)
- Interventions
- Preservative Free Polyethylene glycol 400 0.25%, Propylene Glycol (0.6%), Carboxymethylcellulose sodium 0.5%, Glycerin 1.0%, Polysorbate 80 0.5%
- Drug
- Lead sponsor
- Andover Research Eye Institute
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Vein Occlusion, Macular Degeneration Choroidal Neovascularization, Macular Edema, Diabetic Retinopathy
- Interventions
- Bromfenac Sodium 0.07%, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly, Propylene Glycol Preservative-free Artificial Tears
- Drug
- Lead sponsor
- Retina Research Institute, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- St Louis, Missouri